--------------------------
OMB APPROVAL
--------------------------
OMB Number: 3235-0145
Expires: August 31, 1999
Estimated average burden
hours per response...14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(RULE 13D-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13D-1(B), (C) AND (D) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13D-2(B)
(AMENDMENT NO. ____)*
La Jolla Pharmaceuticals
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
503459109
---------------------------------------------------------------------
(CUSIP Number)
February 9, 2001
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED
IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY
VALID OMB CONTROL NUMBER.
SEC 1745 (3-98) Page 1 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
J.P. Morgan Partners (BHCA), L.P. (formerly known as Chase Equity
Associates, L.P.)
13-3371826
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) .........................................................................
(b) .........................................................................
--------------------------------------------------------------------------------
3. SEC Use Only ...............................................................
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization Delaware
--------------------------------------------------------------------------------
Number of Shares 5. Sole Voting Power 2,055,000
Beneficially Owned -------------------------------------------------------
by Each Reporting 6. Shared Voting Power...........................
Person With: -------------------------------------------------------
7. Sole Dispositive Power 2,055,000
-------------------------------------------------------
8. Shared Dispositive Power......................
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,055,000
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) ........................................................
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9) 5.8%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions) ...............................
--------------------------------------------------------------------------------
PN
................................................................................
................................................................................
................................................................................
................................................................................
................................................................................
................................................................................
--------------------------------------------------------------------------------
SEC 1745 (3-98) Page 2 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
ITEM 1.
(A) NAME OF ISSUER:
La Jolla Pharmaceuticals
(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
6455 Nancy Ridge Drive
San Diego, California 92121
ITEM 2.
(A) NAME OF PERSON FILING:
J.P. Morgan Partners (BHCA), L.P.
Supplemental information relating to the ownership and control
of the person filing this statement is included in
Exhibit 2(a) attached hereto.
(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
1221 Avenue of the Americas
New York, New York 10020
(C) CITIZENSHIP:
Delaware
(D) TITLE OF CLASS OF SECURITIES (OF ISSUER):
Common Stock, par value $0.01 per share
(E) CUSIP NUMBER:
503459109
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR 240.
13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
Not applicable.
ITEM 4. OWNERSHIP
(A) AMOUNT BENEFICIALLY OWNED:
2,055,000
(B) PERCENT OF CLASS:
5.8% (as of December 31, 2001).
SEC 1745 (3-98) Page 3 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
(C) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 2,055,000
shares of Common Stock.
(ii) Shared power to vote or to direct the vote: Not
applicable.
(iii) Sole power to dispose or to direct the disposition
of: 2,055,000 shares of Common Stock
(iv) Shared power to dispose or to direct the disposition
of: Not applicable.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
(a) Not applicable.
(b) By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.
SEC 1745 (3-98) Page 4 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February , 2002
------
J.P. MORGAN PARTNERS (BHCA), L.P.
By: JPMP Master Fund Manager, L.P.,
its General Partner
By: JPMP Capital Corp.,
its General Partner
By: /s/ JEFFREY C. WALKER
----------------------------------
Name: Jeffrey C. Walker
Title: President
SEC 1745 (3-98) Page 5 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
EXHIBIT 2(A)
This statement is being filed by J.P. Morgan Partners (BHCA),
L.P. (formerly known as Chase Equity Associates, L.P.), a Delaware limited
partnership (hereinafter referred to as "JPMP (BHCA)"), whose principal business
office is located at 1221 Avenue of the Americas, New York, New York 10020. JPMP
(BHCA) is engaged in the venture capital and leveraged buyout business. The
general partner of JPMP (BHCA) is JPMP Master Fund Manager, L.P. (formerly known
as Chase Capital Partners, a New York general partnership), a Delaware limited
partnership (hereinafter referred to as "JPMP Master Fund"), whose principal
business office is located at the same address as JPMP (BHCA), and is also
directly or indirectly (through affiliates) engaged in the venture capital and
leveraged buyout business. The general partner of JPMP Master Fund is JPMP
Capital Corp. (formerly known as Chase Capital Corporation), a New York
corporation (hereinafter referred to as "JPMP Capital Corp."), whose principal
business office is located at the same address as JPMP (BHCA), and is also
engaged in the venture capital and leveraged buyout business. Set forth in
Schedule A hereto and incorporated herein by reference are the names, business
addresses, principal occupations and employments of each executive officer and
director of JPMP Capital Corp.
JPMP Capital Corp. is a wholly owned subsidiary of J.P. Morgan
Chase & Co. (formerly known as The Chase Manhattan Corporation), a Delaware
corporation (hereinafter referred to as "JP Morgan Chase") which is engaged
(primarily through subsidiaries) in the commercial banking business with its
principal office located at 270 Park Avenue, New York, New York 10017. Set forth
in Schedule B hereto and incorporated herein by reference are the names,
business addresses, principal occupations and employments of each executive
officer and director of JP Morgan Chase.
SEC 1745 (3-98) Page 6 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
SCHEDULE A
JPMP CAPITAL CORP.
EXECUTIVE OFFICERS(1)
President Jeffrey C. Walker*
Executive Vice President Mitchell J. Blutt, M.D.*
Executive Vice President Arnold L. Chavkin*
Executive Vice President John M.B. O'Connor*
Managing Director Dr. Dana Beth Ardi*
Managing Director John R. Baron*
Managing Director Christopher C. Behrens*
Managing Director David S. Britts*
Managing Director Julie Casella-Esposito*
Managing Director Jerome Colonna*
Managing Director Rodney A. Ferguson*
Managing Director David L. Ferguson*
Managing Director David Gilbert*
Managing Director Eric A. Green*
Managing Director Michael R. Hannon*
Managing Director Donald J. Hofmann, Jr. *
Managing Director W. Brett Ingersoll*
Managing Director Alfredo Irigoin*
Managing Director Andrew Kahn*
Managing Director Jonathan R. Lynch*
Managing Director Thomas G. Mendell*
Managing Director Stephen P. Murray*
Managing Director Timothy Purcell*
Managing Director Faith Rosenfeld*
Managing Director Robert R. Ruggiero, Jr. *
Managing Director Susan L. Segal*
Managing Director Kelly Shackelford*
Managing Director Shahan D. Soghikian*
Managing Director Patrick J. Sullivan*
Managing Director Timothy J. Walsh*
Managing Director Richard D. Waters, Jr. *
Managing Director Damion E. Wicker, M.D.*
Managing Director Eric R. Wilkinson*
Senior Vice President Marcia Bateson*
Senior Vice President and Assistant Secretary Mounir Nahas*
Senior Vice President and Assistant Secretary Stephen Skoczylas*
Senior Vice President, Treasurer and Assistant Secretary Elisa R. Stein*
Vice President and Assistant Secretary Jeffrey Glatt*
Vice President and Assistant Secretary Puneet Gulati*
Vice President and Assistant Secretary Sandra King*
Vice President and Assistant Secretary Scott Kraemer*
Secretary Anthony J. Horan**
Assistant Secretary Robert C. Caroll**
Assistant Secretary Denise G. Connors**
--------
(1) Each of whom is a United States citizen except for Messrs. Britts, Irigoin,
and Soghikian.
* Principal occupation is employee and/or officer of J.P. Morgan Partners,
LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the
Americas, New York, New York 10020.
** Principal occupation is employee or officer of J.P. Morgan Chase & Co.
Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York,
New York 10017.
SEC 1745 (3-98) Page 7 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
DIRECTORS(1)
William B. Harrison**
Jeffrey C. Walker*
--------
(1) Each of whom is a United States citizen except for Messrs. Britts, Irigoin,
and Soghikian.
* Principal occupation is employee and/or officer of J.P. Morgan Partners,
LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the
Americas, New York, New York 10020.
** Principal occupation is employee or officer of J.P. Morgan Chase & Co.
Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York,
New York 10017.
SEC 1745 (3-98) Page 8 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
SCHEDULE B
J.P. MORGAN CHASE & CO.
EXECUTIVE OFFICERS(1)
Chairman of the Board and Chief Executive Officer William B. Harrison Jr.*
Vice Chairman; Co-Chief Executive Officer, Investment Bank Geoffrey T. Boisi *
Vice Chairman; Head of Retail and Middle Market, Financial Services
and Management and Private Banking David A. Coulter*
Director of Human Resources John J. Farrell*
Vice Chairman; Chairman, Investment Bank Walter A. Gubert*
Vice Chairman Thomas B. Ketchum*
Director of Corporate Marketing and Communications Frederick W. Hill*
Vice Chairman; Co-Chief Executive Officer, Investment Bank Donald H. Layton*
Vice Chairman James B. Lee Jr. *
General Counsel William H. McDavid*
Vice Chairman; Head of Finance, Risk Management and Administration Marc J. Shapiro*
Vice Chairman Jeffrey C. Walker**
Executive Vice President; General Auditor William J. Moran*
Chief Financial Officer Dina Dublon*
Executive Vice President; Head of Market Risk Management Lesley Daniels Webster*
Managing Director; Corporate Treasurer David B. Edelson*
Managing Director; Head of Credit Risk Policy Suzanne Hammett*
Corporate Secretary Anthony James Horan*
Senior Vice President; Chief Compliance Officer Gregory S. Meredith*
Controller Joseph L. Scalfani*
Assistant Corporate Secretary James C. Berry*
DIRECTORS(1)
PRINCIPAL OCCUPATION OR EMPLOYMENT;
NAME BUSINESS OR RESIDENCE ADDRESS
--------------------------------------------------------------------------------
Hans W. Becherer Retired Chairman of the Board and
Chief Executive Officer
Deere & Company
One John Deere Place
Moline, IL 61265
--------------------------------------------------------------------------------
Riley P. Bechtel Chairman and Chief Executive Officer
Bechtel Group, Inc.
P.O. Box 193965
San Francisco, CA 94119-3965
--------------------------------------------------------------------------------
Frank A. Bennack, Jr. President and Chief Executive Officer
The Hearst Corporation
959 Eighth Avenue
New York, New York 10019
--------------------------------------------------------------------------------
(1) Each of whom is a United States citizen.
* Principal occupation is employee or officer of J.P. Morgan Chase & Co.
Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York,
New York 10017.
** Principal occupation is employee and/or officer of J.P. Morgan Partners,
LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the
Americas, New York New York 10020.
SEC 1745 (3-98) Page 9 of 10 pages
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
PRINCIPAL OCCUPATION OR EMPLOYMENT;
NAME BUSINESS OR RESIDENCE ADDRESS
--------------------------------------------------------------------------------
Lawrence A. Bossidy Chairman of the Board
Honeywell International
.O. Box 3000
Morristown, NJ 07962-2245
--------------------------------------------------------------------------------
M. Anthony Burns Chairman of the Board
Ryder System, Inc.
3600 N.W. 82nd Avenue
Miami, Florida 33166
--------------------------------------------------------------------------------
H. Laurence Fuller Retired Co-Chairman
BP Amoco p.l.c.
1111 Warrenville Road, Suite 25
Chicago, Illinois 60563
--------------------------------------------------------------------------------
Ellen V. Futter President and Trustee
American Museum of Natural History
Central Park West at 79th Street
New York, NY 10024
--------------------------------------------------------------------------------
William H. Gray, III President and Chief Executive Officer
The College Fund/UNCF
9860 Willow Oaks Corporate Drive
P.O. Box 10444
Fairfax, Virginia 22031
--------------------------------------------------------------------------------
William B. Harrison, Jr. Chairman of the Board and Chief Executive Officer
J.P. Morgan Chase & Co.
270 Park Avenue, 8th Floor
New York, New York 10017-2070
--------------------------------------------------------------------------------
Helene L. Kaplan Of Counsel
Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, New York 10036
--------------------------------------------------------------------------------
Lee R. Raymond Chairman of the Board and Chief Executive Officer
Exxon Mobil Corporation
5959 Las Colinas Boulevard
Irving, TX 75039-2298
--------------------------------------------------------------------------------
John R. Stafford Chairman of the Board
American Home Products Corporation
5 Giralda Farms
Madison, New Jersey 07940
--------------------------------------------------------------------------------
Lloyd D. Ward Chief Executive Officer
U.S. Olympic Committee
One Olympic Plaza
Colorado Springs, CO 80909
--------------------------------------------------------------------------------
Marina v.N. Whitman Professor of Business Administration and Public Policy
The University of Michigan
School of Public Policy
411 Lorch Hall, 611 Tappan Street
Ann Arbor, MI 48109-1220
--------------------------------------------------------------------------------
SEC 1745 (3-98) Page 10 of 10 pages